WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 17, 282-287. Review Article ISSN 2277–7105

HUMAN GENETIC ENHANCEMENT: IMPLICATIONS AND PROSPECTS FOR THE FUTURE OF THE PHARMACEUTICS

Mohd. Shafeuddin Farooqui* and Dr. Rawat Swati

Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, MH, India.

Article Received on
08 July 2024,

Revised on 29 July 2024,
Accepted on 19 August 2024

DOI: 10.20959/wjpr202417-33719

***Corresponding Author**
Mohd. Shafeuddin Farooqui
Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, MH, India.

ABSTRACT

Human genetic enhancement represents a transformative approach in the field of genetic research and its application to enhance human capabilities beyond simple disease treatment. This comprehensive review examines the fundamentals, technologies, applications, and ethical considerations of creation, with particular attention to its intersection with the pharmaceutical field. Through an overview of advances in gene therapy, genome editing, and pharmacogenomics, this article highlights the potential benefits, challenges, and future directions of integrating genetic enhancement with pharmaceutical sciences. The goal of this in-depth analysis is to provide an in-depth understanding of the evolving landscape of genetic enhancement and its implications for the future of drug development and personalized medicine.

1. INTRODUCTION

Human genetic enhancement, an emerging field in genetic research, aims to enhance human traits and capabilities through advanced genetic technologies. Unlike conventional gene therapy, which focuses on treating genetic diseases, genetic enhancement aims to enhance physical, cognitive, or emotional traits. For pharmaceutical experts, understanding these advances is crucial as they have a direct impact on the development of new therapies and personalized medicine approaches.

2. FUNDAMENTALS OF GENETIC ENHANCEMENT

2.1 Genetic Foundations of Human Traits

Human traits are determined by the interaction between genetics and the environment. The human genome consists of approximately 20,000 to 25,000 genes and provides the blueprint for all physiological and cognitive functions.[1] Recent advances in genomics have elucidated the role of specific genes in various traits. For example, research has identified genetic variants associated with intelligence, athletic performance and susceptibility to certain diseases.[2] Understanding these genetic foundations is essential for the effective use of breeding technologies.

2.2 Key Technologies Underlying Genetic Enhancement

Several technologies are at the forefront of genetic enhancement:

• **Gene therapy**: Gene therapy involves altering or replacing genes in a person's cells to treat or prevent a disease. Although gene therapy techniques have traditionally been used for therapeutic purposes, they are increasingly being explored for breeding purposes as well. Advances in viral vector delivery systems and precise gene editing have expanded the potential applications of gene therapy.[3]



Figure 1: Gene Therapy.

• **Genome editing:** Tools such as CRISPR/Cas9 have revolutionized gene editing by enabling precise changes to the DNA sequence. This technology has the potential to enhance human traits, correct genetic defects, or create beneficial changes. The precision and efficiency of genome editing make it a powerful tool for therapeutic and breeding purposes.[4]



Figure 2: CRISPR/Cas9.

• **Pharmacogenomics:** Pharmacogenomics studies how genetic variations affect individual responses to drugs. This area enables the personalization of drug therapies based on genetic profiles, improving drug efficacy and minimizing side effects. Pharmacogenomics is a form of genetic enhancement in the therapeutic context that enables more personalized and effective treatments.[5]

3. APPLICATIONS OF GENETIC EHNHANCMENT IN PHARMACY

3.1 Personalized Medicine

Pharmacogenomics is a key driver of personalized medicine, where treatments are personalized based on genetic profiles. This approach allows the efficacy and safety of drugs to be optimized taking into account individual genetic variations. For example, changes in the CYP450 enzyme system can affect the metabolism of drugs and affect their efficacy and safety.[6] Personalized medicine not only improves treatment outcomes but also reduces the risk of adverse drug reactions.

3.2 Gene Editing and Pharmaceutical Development

Genome editing technologies are transforming pharmaceutical research and development. The creation of genetically engineered cell lines can accelerate drug discovery and testing. For example, genetically engineered cell lines can be used to more efficiently test potential drug candidates or to study disease mechanisms in a controlled environment. In addition, genome editing could enable the development of drugs that specifically target genetic mutations associated with various diseases.[7] These advances promise more precise and effective therapeutic interventions.

3.3 Improving Medicine Delivery Systems

Genetic enhancements can also improve drug delivery systems. By modifying cells or tissues to express specific receptors or transport proteins, drug delivery can be more specific and efficient. For example, engineering cells to express receptors that bind to specific drugs can improve the targeted delivery of therapies to specific tissues or organs.[8] This approach can improve therapy outcomes and minimize side effects, leading to more effective treatments.

4. ETHICAL AND SOCIAL CONSIDERATIONS

4.1 Ethical Issues

Choice research raises several ethical issues:

- **Equity and access:** The availability of creative technologies may be limited to certain socioeconomic groups, which can exacerbate existing health inequalities. Ensuring equitable access to these technologies is a major challenge that requires careful analysis and policy development.[9]
- **Consent and autonomy:** The enhancement of human characteristics through genetic modification raises complex issues related to consent and individual autonomy. Ensuring informed consent is essential because people need to fully understand the potential risks and benefits of genetic enhancement. In addition, respect for personal choices and autonomy is essential in the development and application of these technologies.[10]
- **Long-term impacts**: The long-term impacts of genetic enhancement are not yet fully understood. Unintended consequences or potentially unforeseen impacts on future generations require continuous investigation and monitoring. It is necessary to develop ethical frameworks to address these uncertainties and ensure the responsible use of breeding technologies.[11]

5. FUTURE DIRECTIONS AND CHALLENGES

As enhancement technologies continue to evolve, there are several key areas worth considering:

- **Regulatory frameworks:** Developing robust regulatory frameworks is essential to oversee the development and application of genetic enhancement technologies. These frameworks must address issues of safety, efficiency and ethics to ensure responsible innovation.[12]
- **Public perception and acceptance:** Public perception and acceptance of plant breeding plays a critical role in shaping its future. Engaging the public and addressing concerns through education and dialogue can facilitate informed decision-making and support for breeding initiatives.[13]
- **Integration into existing therapies:** Integrating genetic enhancement technologies into existing pharmaceutical therapies presents opportunities and challenges. Collaboration between genetic researchers, pharmaceutical developers and healthcare professionals is essential to optimize therapeutic approaches and ensure patient safety.[14]

6. CONCLUSION

Human genetic enhancement represents an opportunity for change in the pharmaceutical field. By integrating advances in gene therapy, genome editing and pharmacogenomics, the potential for developing effective, personalized therapies is immense. However, it is important to consider the ethical and social implications to advance these technologies responsibly. It is important for pharmacy professionals to stay up to date with these advances and understand their impact to contribute to the future of personalized medicine and pharmaceutical innovation.

REFERENCES

1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. *Nature*, 2001; 409(6822): 860-921. doi:10.1038/35057062
2. Plomin, R., Deary, I. J., & Spinath, F. M. Intelligence: Genetics and neuroscience. *Perspectives on Psychological Science*, 2004; 1(3): 162-175. doi:10.1111/j.1745-6916.2006.00012.x
3. High, K. A., & Roncarolo, M. G. Gene therapy. *New England Journal of Medicine*, 2019; 381: 455-464. doi:10.1056/NEJMra1706166

4. Doudna, J. A., & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. *Science*, 2014; 346(6213): 1258096. doi:10.1126/science.1258096
5. Johnson, J. A., & Roden, D. M. Pharmacogenomics: Current applications and future directions. *American Journal of Health-System Pharmacy*, 2007; 64(11): 1132-1138. doi:10.2146/ajhp070071
6. McCarthy, M. I., & Hirschhorn, J. N. Genome-wide association studies: Potential next steps on a genetic journey. *Nature Reviews Genetics*, 2008; 9(5): 316-328. doi:10.1038/nrg2333
7. Lander, E.S. The Heroes of CRISPR. *Cell*, 2016; 164(1-2): 18-28. doi:10.1016/j.cell.2015.12.041
8. Shapiro, R. M., & Goodman, J.R. Genetically engineered cell-based drug delivery systems. *Journal of Controlled Release*, 2019; 300: 150-163. doi:10.1016/j.jconrel.2019.02.030
9. Sweeney, M. M., & Godard, B. Ethics and policy in genetic enhancement: A comparative perspective. *Genomics, Society and Policy*, 2009; 5(1): 1-14. doi:10.1186/1746-5354-5-1-1.
10. Liao, S. M., & Sandel, M. Enhancement and the importance of informed consent. *Bioethics*, 2016; 30(2): 124-130. doi:10.1111/bioe.12217
11. Green, R. C., & Spector-Bagdady, K. The clinical and ethical implications of gene editing technologies. *JAMA*, 2020; 323(13): 1281-1282. doi:10.1001/jama.2020.10555
12. Kahn, J. P., & Fins, J. J. Regulating genetic enhancement: A new framework. *American Journal of Bioethics*, 2019; 19(3): 1-12. doi:10.1080/15265161.2018.1552424
13. Davis, M. M., & Klein, E. Public perception of genetic enhancement: A survey-based approach. *Genetics in Medicine*, 2017; 19(9): 1015-1021. doi:10.1038/gim.2017.15
14. Collins, F. S., & Varmus, H. A new era in biomedical research. *Science*, 2015; 348(6230): 36-40. doi:10.1126/science.aab0815